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Abstract
Regular fish or fish oil intake is associated with a low incidence of heart failure clinically, and fish oil-induced reduction in cardiac remo-
delling seen in hypertrophy models may contribute. We investigated whether improved cardiac energy efficiency in non-hypertrophied
hearts translates into attenuation of cardiac dysfunction in hypertrophied hearts. Male Wistar rats (n 33) at 8 weeks of age were sham-
operated or subjected to abdominal aortic stenosis to produce pressure-overload cardiac hypertrophy. Starting 3 weeks post-operatively
to follow initiation of hypertrophy, rats were fed a diet containing 10 % olive oil (control) or 5 % fish oil (ROPUFAw 30 (17 % EPA,
10 % DHA)) þ 5 % olive oil (FO diet). At 15 weeks post-operatively, ventricular haemodynamics and oxygen consumption were evaluated
in the blood-perfused, isolated working heart. Resting and maximally stimulated cardiac output and external work were .60 % depressed
in hypertrophied control hearts but this was prevented by FO feeding, without attenuating hypertrophy. Cardiac energy efficiency was
lower in hypertrophy, but greater in FO hearts for any given cardiac mass. Coronary blood flow, restricted in hypertrophied control
hearts, increased with increasing work in hypertrophied FO hearts, revealing a significant coronary vasodilator reserve. Pronounced
cardiac dysfunction in hypertrophied hearts across low and high workloads, indicative of heart failure, was attenuated by FO feeding
in association with membrane incorporation of n-3 PUFA, principally DHA. Dietary fish oil may offer a new approach to balancing the
high oxygen demand and haemodynamic requirements of the failing hypertrophied heart independently of attenuating hypertrophy.
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Despite declining heart disease mortality rates, a continuing
rise in heart failure incidence is of major clinical concern in
many nations(1). Regular fish (and hence n-3 PUFA) consump-
tion is associated with low CVD mortality(2,3). Antiarrhythmic
effects first identified in animal models(4) are evident in clinical
studies showing reduced incidence of primary cardiac arrest(5)
and post-infarction arrhythmic deaths(6), and represent the
best-supported mechanism of action. However, in addition
to arrhythmia prevention, alternative mechanisms of fish oil
action, such as prevention of heart failure, are implicated
directly from epidemiology(7), and indirectly as reduced
non-arrhythmic but otherwise unspecified cardiac deaths
and post-infarction deaths(8). These clinical outcomes are
independent of dietary n-3 PUFA effects on classic risk factors
such as plasma TAG and thrombogenic factors(9) or blood
pressure(8,10). Animal studies have described fish oil-induced
improvements in heart function and the prevention of fatal
arrhythmia in non-disease states that are associated with the
incorporation of the long-chain n-3 PUFA DHA into myocar-
dial membranes(4,11–14) and occur at lower intakes than for
the vascular effects(15).
Hearts isolated from rats fed fish oil exhibit significantly
reduced oxygen consumption without compromise to cardiac
output (CO) or external work(13). This represents increased
energy efficiency of oxygen use, increased coronary perfusion
reserve, less damage in acute ischaemia and reduced myocar-
dial stunning(13,16,17). Cardiac hypertrophy is generally charac-
terised by morphological and biochemical changes that
predispose to myocardial ischaemia through disturbances of
both oxygen supply and demand at the cellular level, which
promote energetic failure and heart failure(18). For example,
high ventricular wall tension increases oxygen demand and
restricts coronary blood flow, compromising oxygen delivery
to myocardial mitochondria already jeopardised by high
inter-capillary distances. The capacity of the hypertrophied
cell to use oxygen has reportedly been further reduced by
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a high ratio of contractile protein:mitochondria, and mito-
chondrial function itself may be compromised(18). Conse-
quently, an intervention that reduces myocardial oxygen
consumption (MVO2) without detriment to myocardial work
output could improve cardiac function in hypertrophy and
retard the progression to failure(19).
The present study tests the hypothesis that incorporation of
n-3 PUFA into myocardial membranes through fish oil feeding
will improve cardiac energy efficiency and attenuate cardiac
dysfunction and heart failure in the hypertrophied heart.
Methods
A total of thirty-three male Wistar rats (CSIRO Human Nutri-
tion, Adelaide, Australia) were used in the present study.
The experiments were conducted according to the National
Health and Medical Research Council of Australia, Guidelines
for the Use of Experimental Animals, and were approved by
the Animal Care and Ethics Committees of the University of
Wollongong and CSIRO Human Nutrition.
Animal model of pressure-overload hypertrophy
Under ketamine (70 mg/kg) þ xylazine (5 mg/kg) anaesthesia,
twenty-eight rats were subjected to restrictive banding of the
suprarenal abdominal aorta at 8 weeks of age using a blunt
23G needle as a template. The needle was tied tightly against
the aorta above the renal arteries (causing visible kidney
blanching), and then removed, leaving the suture in place to
partially restore blood flow (visually confirmed). Another five
rats were subjected to sham operation without aortic restriction.
Heart function was assessed 15 weeks post-operatively.
Cardiac hypertrophy was determined from the heart weight:
body-weight ratio and the heart weight:tibia length ratio. The
latter index is not distorted by acute fluctuations in body
weight or body-weight gain from fluid retention. Cardiac
hypertrophy was defined as a ratio . 2 SD above the mean
for rats of the same strain and age as those in the present
study. The pooled mean of ventricle dry weight:tibia length
from fifty-three rats previously recorded in this laboratory,
not subjected to surgical intervention, was 0·376 (SD
0·045) g/cm. Cardiac hypertrophy was therefore defined for
this strain and age of rat as a ventricle weight:tibia length
ratio . 0·466 g/cm.
The pressure overload induced by aortic stenosis provokes
a hypertrophic response within 4 d, and it has been well
established by 3 weeks(20). Because fish oil inhibits cardiac
hypertrophy when presented before and during a hypertrophic
stimulus(21,22), in the present study, the initiation of fish oil
feeding was delayed until 3 weeks after surgery in order to
focus interpretation on pathophysiology of the hypertrophied
heart. The aortic stenosis model was preferred to alternative
models of the following: aortic valve disruption (volume over-
load), which is unsuitable for evaluation in the isolated working
heart preparation; and coronary artery occlusion (chronic myo-
cardial infarction), which is prone to a high incidence of acute
fatal arrhythmia and potentially confounding effects of tissue
repair processes that may be influenced by dietary intervention
independently of the effects on hypertrophic function.
Diets
Rats were fed an olive oil (OO) control diet for 4 weeks before
surgery and 3 weeks post-operatively. They were then ran-
domly allocated to either the fish oil (FO) diet or the OO con-
trol diet for 12 weeks. Sham-operated rats were fed the OO
control diet throughout the experiment. Isoenergetic fully fab-
ricated diets were prepared(16,23) containing 100 g/kg diet as
fat. The OO (control) diet contained 10 % (by weight) olive
oil, and the FO diet contained 5 % olive oil plus 5 % fish oil.
The olive oil was commercially available food-grade olive
oil, refined to exclude antioxidant phytochemicals. The fish
oil (ROPUFAw 30 n-3 EPA oil; DSM Nutritional Products,
Basel, Switzerland) contained 16·8 % EPA (20 : 5n-3) and
9·7 % DHA (22 : 6n-3; 32·5 % total n-3 fatty acids). Olive oil
was selected for the isoenergetic control diet on the basis of
the following: its main component (monounsaturated oleic
acid (18 : 1)) being a physiologically neutral fat; and the oil
providing sufficient PUFA to avoid essential fatty acid
deficiency(16). Although n-3 PUFA replace n-6 PUFA in myo-
cardial membranes, the long-chain n-3 PUFA are incorporated
in direct relationship to their absolute quantities in the diet
and independently of dietary MUFA or n-6 PUFA dietary
concentrations(23). The main fatty acid components of the
two diets were as follows: total SFA (OO 14 %; FO 22 %);
total PUFA (OO 10 %; FO 22 %); oleic acid (18 : 1; OO 76 %;
FO 45 %); linoleic acid (18 : 2n-6; OO 8·3 %; FO 5·2 %); EPA
(FO 8·4 %); DHA (FO 4·9 %).
Isolated working heart
Rats were anaesthetised (pentobarbitone sodium 60 mg/kg
intraperitoneally), and the right common carotid artery and
the left femoral artery were cannulated to record arterial
blood pressures proximal and distal to the aortic stenosis.
Rats were then killed by rapid exsanguination and the hearts
removed into ice-cold saline and prepared for working heart
perfusion with porcine erythrocyte buffer (40 % haematocrit
in Krebs Henseleit solution) as described previously(13).
Briefly, the aorta, left atrium and pulmonary artery were can-
nulated and the heart perfused with Krebs Henseleit solution
in Langendorff mode for 10 min for rat blood washout.
Hearts were switched to working heart mode and perfused
with erythrocyte buffer via the left atrium with 10 mmHg filling
pressure (preload) and 75 mmHg diastolic aortic pressure
(afterload, coronary perfusion pressure). A catheter intro-
duced through silicone self-sealing tubing supplying the left
atrium and fed into the ventricle via the mitral valve recorded
left ventricular pressure. Working hearts were allowed to
stabilise for 15 min.
Cardiac function
CO and coronary flow were measured at 5 min intervals by
timed overflow, with coronary and aortic samples collected
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for the measurement of arterial and venous blood gases and
pH. Stroke volume (SV) was calculated from the CO and
heart rate. MVO2 was derived from arterio-venous oxygen
differences per unit coronary flow, and external work was
derived from the CO and developed pressure (CO £ mean
aortic pressure) as described previously(13). Cardiac energy
efficiency (%) was calculated as the ratio of energy derived
from MVO2 (in kJ) to energy delivered as external work (in
kJ) £ 100. After equilibration, preload was changed over the
range 5–20 mmHg by altering ventricular filling pressure,
before returning pressure to 10 mmHg for recovery. Intraven-
tricular pressure, aortic pressure and electrocardiogram were
recorded continuously, while coronary and aortic flows were
measured and blood samples were collected at 5 min intervals.
Membrane fatty acids
Hearts were rinsed in ice-cold saline, blotted dry and weighed.
A small section of the ventricle free wall was weighed and
retained for dry-weight estimation. The remaining ventricle
was rapidly frozen using liquid N2-cooled clamps and then
frozen at 2608C until required for fatty acid measurement
according to established methods(23). In brief, samples of the
frozen tissue were pulverised over liquid N2 and washed
with centrifugation to remove sucrose. Lipids were extracted
using chloroform–methanol with aliquots applied to silicic
acid columns to separate neutral lipids and phospholipids.
Fatty acid methyl esters of the phospholipids were prepared
and extracted for analysis by GC. Fatty acids were identified
from their retention times compared with those of authentic
methyl fatty acid standards.
Statistical analysis
The CO, external work, coronary flow, oxygen extraction
and MVO2 were expressed 1/g ventricle dry weight. Results
are expressed as means with their standard errors. For hae-
modynamic measures, two-way ANOVA was conducted with
diet and hypertrophy main effects and diet £ hypertrophy
interaction. Individual comparisons between diet £ hyper-
trophy were conducted using Scheffe’s post hoc F test for
multiple comparisons of individual means. Values in tables
sharing a common superscript letter were not significantly
different. The level of significance was considered at
P,0·05.
Results
Heart and body weights, blood pressure and cardiac
hypertrophy
Cardiac enlargement sufficient to classify as hypertrophy
occurred in six of the fourteen rats in each of the dietary
groups subjected to abdominal aortic stenosis. Rats with car-
diac hypertrophy (designated OOH if fed the olive oil diet
and FOH if fed the FO diet) had significantly greater ventricle
weights and body weights than non-hypertrophied (desig-
nated OO or FO) or sham-operated rats (Table 1). Tibia
length, body weight, body size or heart weight were not
different between the dietary groups within either the hyper-
trophy or non-hypertrophy animals (Table 1). Less variation
in tibia length than in body weight resulted in the ventricle
weight:tibia length being the clearer discriminator of
hypertrophy.
Table 1. Effect of diet and cardiac hypertrophy on animal characteristics and isolated working heart function at equilibrium
(Mean values with their standard errors)
Diet group. . . OO OOH FO FOH
Sham control
(n 5)
No hypertrophy
(n 8)
Hypertrophy
(n 6)
No hypertrophy
(n 8)
Hypertrophy
(n 6)
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Body weight (g) 477 10 442 13 504 28 468 15 486 16
Atria weight (g) 0·12 0·01 0·12 0·01 0·19 0·03 0·12 0·01 0·15 0·02
Ventricle weight (g) 1·66b 0·06 1·49b 0·05 2·23a 0·10 1·69b 0·06 2·10a 0·07
Ventricle dry weight (g) 0·27b 0·01 0·27b 0·01 0·39a 0·01 0·31b 0·01 0·38a 0·02
Dry:wet left ventricle weight 0·163 0·005 0·185 0·004 0·175 0·007 0·188 0·002 0·184 0·002
Tibia length (cm) 4·16 0·01 4·15 0·04 4·13 0·07 4·26 0·07 4·16 0·06
Ventricle weight:tibia length (g/cm) 0·400b 0·021 0·359b 0·012 0·545a 0·030 0·397b 0·015 0·503a 0·014
Ventricle weight:body weight (g/100 g) 0·348b 0·010 0·338b 0·011 0·455a 0·031 0·363b 0·017 0·436a 0·032
Heart weight:body weight (g/100 g) 0·373b 0·014 0·356b 0·014 0·488a 0·039 0·386b 0·022 0·443a 0·039
Carotid systolic BP (mmHg) 146b 14 161b 19 220a 20 166b 17 218a 19
Carotid diastolic BP (mmHg) 118b 13 131b 17 165a 13 131b 12 164a 15
Femoral systolic BP (mmHg) 166a 13 134b 16 136b 13 135b 19 148a,b 15
Femoral diastolic BP (mmHg) 125 16 100 14 111 12 114 16 118 14
Isolated working heart at equilibrium
Heart rate (beats per min) 207 26 203 23 185 24 211 14 210 19
Cardiac output (ml/min per g dry weight) 82b,c 19 108a,b 22 56c 20 128a,b 33 127a 20
Coronary flow (ml/min per g dry weight) 33·7a 4·7 34·3a 6·2 17·3b 3·9 30·2a 6·1 40·6a 4·8
Ventricle dP/dtmax (mmHg/s) 3070 194 3634 503 2389 452 3233 388 3236 317
Ventricle 2dP/dtmax (mmHg/s) 2460
b 269 2608b 355 1632a 278 2351b 292 2560b 320
OO, olive oil diet; OOH, rats with cardiac hypertrophy fed with an olive oil diet; FO, fish oil diet; FOH, rats with cardiac hypertrophy fed with a fish oil; BP, blood pressure.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P,0·05).
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Femoral artery pressure was significantly lower (P,0·05) in
rats subjected to aortic stenosis than in sham-operated controls
and did not differ between the rats with or without cardiac
hypertrophy or between the dietary groups (Table 1). Carotid
artery pressure was significantly higher in animals with cardiac
hypertrophy compared with those that failed to develop
hypertrophy or sham-operated controls (P,0·05). There
were no significant differences in carotid blood pressures
between the dietary groups.
Equilibrium heart function
Under initial conditions of the 10 mmHg preload and the
75 mmHg afterload, there were no differences in spontaneous
resting heart rate (Table 1). Uncorrected CO (ml/min) was sig-
nificantly higher in hearts from fish oil-fed rats (FO 41·3 (SEM
10·9); FOH 48·1 (SEM 10·5)) than in hearts from rats fed olive
oil (sham 20·1 (SEM 4·7); OO 29·0 (SEM 3·9); OOH 21·9 (SEM
7·6)) (P,0·01), with no significant interaction (P.0·05).
When corrected for ventricular mass, the CO of the hypertro-
phied OOH hearts was significantly lower per gram of tissue
(P,0·05) than the OO, FO and hypertrophied FOH hearts
(Table 1). The CO of the FOH (hypertrophied) hearts was
not significantly different from that of the FO (non-hypertro-
phied) hearts. There was a significant (diet £ hypertrophy)
interaction for the maximum rate of ventricular relaxation
(P¼0·02) and the OOH hearts showed a significantly slower
relaxation rate than all the other hearts (P,0·05; Table 1).
Coronary flow did not differ among the non-hypertrophied
hearts but was significantly lower in the OOH hearts (P,0·01)
than all the other hearts (Table 1). The MVO2 at equilibrium in
the non-hypertrophied hearts did not differ between the diet-
ary groups or the sham-operated control but was higher in the
FOH hearts and lower in the OOH hearts relative to all the
other hearts (P,0·05; Fig. 1). External work was significantly
lower in the OOH hearts (P,0·01) than in the OO, FO and
FOH hearts (Fig. 1).
The hypertrophied hearts had significantly lower energy
efficiency than the non-hypertrophied hearts (two-way
ANOVA (diet, hypertrophy), P,0·05) and the FO hearts
had higher cardiac efficiency than the OO hearts (P,0·05).
Cardiac energy efficiency was significantly lower in the
OOH hearts than in the OO, FO and FOH hearts (Fig. 1).
Cardiac function under load
The CO, SV (Fig. 2) and external work (Fig. 3) increased with
increasing filling pressure (preload) (P,0·0001). The hypertro-
phied hearts had a lower SV, CO or external work over the
range of filling pressures (P,0·0001). A significant (diet £
hypertrophy) interaction was evident for SV (P¼0·01), CO
(P¼0·023) and external work (P¼0·044). The OOH hearts had
a significantly lower SV (P,0·0001), CO (P,0·0001) and exter-
nal work (P,0·0001) than the OO hearts, while there were
no significant differences between the FOH and FO hearts
(SV P¼0·10; CO P¼0·082; external work P¼0·51). Among the
hypertrophied hearts, the FOH group had a significantly higher
SV (P¼0·008), CO (P¼0·003) and external work (P¼0·003)
than the OOH hearts across the range of filling pressures.
Coronary flow and MVO2 increased with increasing filling
pressure (P,0·04; Fig. 2). A significant (diet £ hypertrophy)
interaction was evident for coronary flow (P¼0·01) and MVO2
(P¼0·002). Coronary flow over the range of filling pressures
was significantly lower in the OOH hearts than in the FOH
(P¼0·015) and OO hearts (P¼0·0005). The MVO2 was not
significantly different in the FOH hearts compared with the
FO hearts (P¼0·19), and there were no significant differences
in coronary flow (P¼0·12) or MVO2 (P¼0·059) between the
OO and FO hearts. The cardiac energy efficiency of oxygen
conversion into external work increased (P¼0·0003) as external
work was increased by increasing filling pressure (Fig. 3), and it
was significantly lower in hypertrophy (P,0·0001) with both
diets. No significant (diet £ hypertrophy) interaction was evi-
dent for cardiac energy efficiency (P¼0·87). Cardiac efficiency
was higher in the FO hearts than in the OO and sham hearts
(P¼0·004) and higher in the FOH hearts than in the OOH
hearts (P¼0·004).
Membrane composition
The phospholipid fatty acid composition of the rat hearts was
significantly influenced by the fat source in the diet. The FO
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Fig. 1. Effects of fish oil (FO) on (a) cardiac external work, (b) myocardial oxygen consumption (MVO2) and (c) cardiac energy efficiency in the isolated working
heart without hypertrophy (olive oil (OO; ), FO ( )) or with hypertrophy (OOH ( ), FOH ( )). Values are means, with their standard errors represented by verti-
cal bars (n 6–8 per group). * Mean values were significantly different from those of the no-hypertrophy group (P , 0·05, ANOVA). † Mean values were significantly
different for diet £ hypertrophy interaction (P , 0·05; ANOVA). ‡ Mean values were significantly different for FO from those of the OO control diet (P,0·05;
ANOVA). § Mean values were significantly different for FOH from those of the OOH group (P,0·05; ANOVA).
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diet significantly increased the concentration of n-3 PUFA EPA
and DHA and reduced the concentration of monounsaturated
oleic acid and the n-6 PUFA arachidonic acid compared with
the OO diet (Table 2). The total saturated fat concentration
was unaltered but the total PUFA concentration and the unsa-
turation index were increased with FO feeding.
The hypertrophied OOH hearts incorporated significantly
less linoleic acid (P,0·05) with non-significant trends towards
increased arachidonic acid (P,0·1) and DHA (P,0·1), produ-
cing, overall, a non-significant trend towards reduced n-6
PUFA (P,0·1) and a small but significant increase in unsatura-
tion index (P,0·05) compared with the non-hypertrophied
OO hearts (Table 2). There were no significant differences
in phospholipid fatty acid composition between the hypertro-
phied (FOH) and non-hypertrophied (FO) fish oil hearts.
Discussion
The results of the present study demonstrate that incorpor-
ation of n-3 PUFA into myocardial cellular membranes to
reduce MVO2 in relation to the cardiac work output seen in
normal hearts(13) translates into attenuation of cardiac dys-
function in the hypertrophied hearts. Fish oil feeding is
known to limit the development of cardiac hypertrophy
induced by a variety of stimuli(21,22,24,25), and until now, any
attenuation of hypertrophied heart dysfunction by n-3 PUFA
was always accompanied by, and could not be differentiated
from, the prevention of ventricular remodelling(21,24). Our
demonstration that hypertrophied heart function was
improved independently of attenuating cardiac hypertrophy
suggests that dietary fish oil may prevent cardiac dysfunction
progressing to heart failure. The improved cardiac function,
demonstrated not only at rest (as previously shown in associ-
ation with hypertrophy attenuation(21,24)), but over a wide
range of loading conditions and functional measures, provides
further support.
Fish oil improvement of cardiac function was largely limited
to the hypertrophied hearts, even though myocardial energy
efficiency was significantly greater with fish oil feeding in
the non-hypertrophied hearts. Improved oxygen efficiency
often does not translate into cardiac function improve-
ment in healthy, well-oxygenated hearts(13,24). However,
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Fig. 2. Effects of fish oil (FO) and cardiac hypertrophy on (a) stroke volume (SV), (b) cardiac output (CO), (c) coronary flow and (d) myocardial oxygen consump-
tion (MVO2) in the isolated working heart during changes in ventricular filling pressure: sham-operated olive oil (OO) control diet ( , ), OO control diet ( , no
hypertrophy; , hypertrophy (OOH)), FO diet ( , no hypertrophy; , hypertrophy (FOH)). Values are means, with their standard errors represented by vertical
bars (n 6–8 per group). * Mean values were significantly different from those of the sham OO control (P , 0·05; ANOVA). † Mean values were significantly differ-
ent for diet £ hypertrophy interaction (P , 0·05; ANOVA).
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energy-sparing effects consistently translate into improved
heart function under cardio-depressant stress conditions
such as myocardial ischaemia(13,16) or cardiac hypertrophy.
Attenuation of the decline in CO, the decline in cardiac relax-
ation and filling, the depressed external work and energy effi-
ciency, over the entire Frank–Starling relationship, especially
at high workload, illustrates the potential for translation
across all stages of heart failure.
Increased ventricular stiffness impairs relaxation and filling,
increases the work of contraction, impairs cardiac energetics,
prolongs coronary artery compression and impairs coronary
perfusion(18,19,26). It is therefore a major contributor to cardiac
dysfunction. Retention of residual wall tension was less evi-
dent in the hypertrophied fish oil hearts by virtue of better car-
diac relaxation. The hypertrophy-induced reduction in cardiac
energy efficiency was attenuated by fish oil feeding, and the
hypertrophied fish oil hearts did not display the depressed
rate of relaxation, ventricle filling and CO usually associated
with post-adaptive cardiac hypertrophy. Furthermore, the
increase in coronary vasodilator reserve associated with fish
oil in healthy hearts(13,16) translated into an adaptive increase
in oxygen delivery in the hypertrophied hearts during the
demand of raised filling pressure, overcoming the normally
depressed coronary flow and providing further advantage in
pathophysiological conditions.
Potential mechanisms of n-3 PUFA actions
Impaired relaxation, contraction and energetic failure under-
pinning the pathophysiology of cardiac dysfunction and
heart failure are all associated with altered myocardial Ca2þ
homeostasis. In turn, energetic failure leads to altered Ca2þ
handling, creating a vicious cycle(18). Conversely, numerous
effects of the long-chain n-3 PUFA on myocardial Ca2þ regu-
lation have biologically plausible correlates in the effects of
dietary fish oil on hypertrophied heart function that might
play a role in breaking that cycle(14). For example, pathologi-
cal depolarisation and cardiac arrhythmias may be attenuated
by the following: inhibition of phospholipase-C and to
thereby attenuate inositol trisphosphate and diacylglycerol
mobilisation from membrane phospholipids, which in turn
attenuates Ca2þ mobilisation, particularly in response to
ischaemic stress; reducing sarcoplasmic reticulum (SR)- Ca2þ
overload and attenuating Ca2þ sparks(14,27). Hypertrophied
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Fig. 3. Effects of dietary oil and cardiac hypertrophy on (a, b) cardiac external work and (c, d) cardiac energy efficiency in the isolated working heart during
changes in ventricular filling pressure. (a, c) Sham and non-hypertrophied hearts. (b, d) Sham and hypertrophied hearts. Sham-operated olive oil (OO) control diet
( , ), OO control diet ( , no hypertrophy; , hypertrophy (OOH)) and FO diet ( , no hypertrophy; , hypertrophy (FOH)). Values are means, with their stan-
dard errors represented by vertical bars (n 6–8 per group). * Mean values were significantly different from those of the sham OO control (P , 0·05; ANOVA).
† Mean values were significantly different for diet £ hypertrophy interaction (P , 0·05; ANOVA).
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heart dysfunction may be attenuated by the following: inhibit-
ing mitochondrial Ca2þ overload to attenuate excess oxygen
consumption(13,28); and limiting pathological increases in cyto-
solic free Ca2þ and cellular Ca2þ transients to reduce residual
wall stiffness and improve relaxation and filling(29,30).
In the present study, use of the isolated, blood-perfused,
working heart model allows us to draw conclusions about
the intrinsic role of membrane incorporation of the n-3
PUFA(14) by excluding nervous or humoral influences or
effects of circulating fatty acids. Myocardial phospholipid
DHA concentration increased much more than EPA, produ-
cing relative concentrations of 15:1 in the myocardial
membranes, despite a dietary DHA:EPA ratio of less than 1:2
favouring EPA. In the rat heart, DHA, and not EPA, is incor-
porated well above its circulating levels and its dietary
concentration(31), and DHA is preferentially incorporated
into myocardial tissue in rats and in human subjects(12,14,32)
even when the diet favours EPA as in the present study, or
contains only very low intakes of fish oil(23,24). DHA is the
principal n-3 PUFA in most table fish and is the key n-3
PUFA modulating cardiac function directly through membrane
composition(14,15). For example, ischaemic arrhythmias are
not prevented by increases in membrane EPA when the
DHA increase is inadequate(15). While not denying a role for
EPA in inflammatory and other signalling processes in blood,
vasculature and other tissues(27,33), membrane DHA status is
consistent with clinical evidence of direct myocardial effects
of dietary fish and fish oil. For whereas fish and fish oil
reduce heart rate, heart failure and sudden cardiac
death(5,7,8,10,34) without preventing new (vascular) ischaemic
events(8,10), purified EPA used in a major clinical trial pre-
vented new vascular ischaemic events without reducing
sudden cardiac death(35). The reduction in membrane arachi-
donic acid with fish oil feeding implies a role for reduced
eicosanoid production. However, earlier studies have shown
variable relationships between the availability of arachidonic
acid in myocardial membranes and the ability of fish oils
and other dietary fats to modulate myocardial eicosanoid
production and pathophysiological responses such as
cardiac arrhythmia(36,37). Alternatively, DHA can inhibit the
cyclo-oxygenase and lipoxygenase production of potent
eicosanoids derived from arachidonic acid, and can also
inhibit MAP kinase-stimulated Ca2þ-activated phospholipase-D
to restrict arachidonic acid mobilisation from membrane
phospholipid(27). In addition to influencing eicosanoid
mechanisms, n-3 PUFA can directly modulate a wide range
of Ca2þ-handling cellular processes and other intracellular
signalling processes involved in Ca2þ mobilisation and
cardiac contractile function(14,27). However, much of the cell
signalling data are derived from in vitro studies, and are yet
to be verified after dietary incorporation of the n-3 PUFA
into cell membranes.
Table 2. Effect of cardiac hypertrophy and ROPUFAw 30 dietary fish oil supplementation on myocardial total phos-
pholipid fatty acid composition§
(Mean values with their standard errors, n 5)
Percentage of occurrence{
OO OOH FO FOH
Diet Mean SEM Mean SEM Mean SEM Mean SEM
Fatty acid
16 : 0 9·98 0·28 10·82‡ 0·24 11·08 0·26 11·43 0·24
18 : 0 22·76 0·24 21·11 0·32 21·89 0·24 22·14 0·24
18 : 1n-7 4·71 0·12 4·02 0·15 4·22 0·09 4·17 0·04
18 : 1n-9 (OA) 10·83 0·45 10·47 0·41 6·34* 0·35 6·22† 0·24
18 : 2n-6 (LA) 12·72 0·54 8·17‡‡ 0·64 10·08 0·61 9·51 0·65
20 : 4n-6 (AA) 20·56 0·37 21·73‡ 0·41 14·60* 0·32 14·11† 0·56
20 : 5n-3 (EPA) 0·05 0·04 0·06 0·02 1·42 0·04 1·28 0·05
22 : 4n-6 0·41 0·04 0·69 0·02 ND ND
22 : 5n-3 or 24 : 0 0·82 0·12 1·00 0·11 3·52* 0·10 3·46† 0·12
22 : 5n-6 1·72 0·30 2·18 0·24 0·31* 0·10 0·19† 0·02
22 : 6n-3 (DHA) 9·32 0·34 11·37‡ 0·95 20·68* 0·74 19·91† 0·88
Total fatty acids 93·88 0·77 93·56 0·87 94·14 0·50 95·17 0·33
Sum SFA 32·74 0·54 33·43 0·60 32·97 0·46 34·12 0·09
Sum MUFA 15·54 0·41 15·25 0·45 10·56* 0·36 11·51† 0·25
Sum PUFA 45·60 0·46 44·89 0·49 50·61* 0·62 49·14 0·46
Total n-3 PUFA 10·19 0·56 11·43 0·97 25·62* 0·88 24·65† 0·93
Total n-6 PUFA 35·41 0·88 32·76‡ 0·93 24·99* 0·93 23·82† 1·18
n-6:n-3 3·47 0·25 2·99 0·39 0·98* 0·10 0·98† 0·08
UI 193·7 2·5 202·4‡‡ 2·8 239·5* 3·0 233·0† 2·6
OO, olive oil diet; OOH, rats with cardiac hypertrophy fed with an olive oil diet; FO, fish oil diet; FOH, rats with cardiac hypertrophy
fed with a fish oil; OA, oleic acid; LA, linoleic acid; AA, arachidonic acid; ND, not detected; UI, unsaturation index.
* Mean values were significantly different for FO from those of the OO group (P,0·05).
† Mean values were significantly different for FOH from those of the OOH group (P,0·05).
Mean values were significantly different from those of the OO group: ‡‡ P,0·05 (‡ P,0·10; NS).
§ Fatty acid terminology – X:Y n 2 Z represents the length of the carbon chain (X), the number of double bonds (Y) and the position
of the first double bond from the methyl-terminal end (n 2 Z). Total fatty acids represent the percentage of peaks identified.
{Percentage of occurrence refers to all measures except n-6:n-3 (a ratio) and UI which represents the sum of (fatty acid percentage
of occurrence £ number of double bonds).
Fish oil and heart failure 651
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114511005915
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:39:37, subject to the Cambridge Core terms of use, available at
With more membrane manufactured as cells enlarge,
hypertrophy-driven changes have the potential to alter myo-
cardial phospholipid composition and modify responses to
dietary intervention. Indeed, adaptive decreases in linoleic
acid and increases in arachidonic acid, DHA and membrane
total unsaturation that occur in response to a variety of stres-
sors(38), including pressure overload(20,24) and catecholamine
stress(39), were observed in the present study. However,
none of the adaptive changes were as great as changes
induced by the FO diet. Any hypertrophy-associated increases
in DHA and total unsaturation were overwhelmed by the diet-
ary intervention and the arachidonic acid increase was
reversed, such that no differences were evident between the
hypertrophied and non-hypertrophied fish oil hearts.
Comparison with therapeutic interventions to enhance
cardiac function
Dietary fish oil-induced improvement of hypertrophied heart
contractile function has some similarities but many differences
to therapeutic interventions used in the treatment of heart
failure. For example, positive inotropic agents typically
improve systemic haemodynamics and provide symptomatic
relief in heart failure by increasing contractility at the expense
of reduced energy efficiency(40), increased risk of ischae-
mia(41), cardiac arrhythmias and increased early mortality.
Vasodilators relieve heart failure by reducing systemic blood
pressure and unloading the heart, which the fish oil did not
do in the present study. Moreover, the negative inotropic
actions of the Ca2þ channel blocking class of vasodilators(42)
are inconsistent with the effects of fish oil. The angiotensin-
converting enzyme (ACE) inhibitors and angiotensin receptor
antagonists have no direct effect on myocardial contractile
performance, acting principally by inhibiting hypertrophy
and myocardial fibrosis(43,44), whereas fish oil directly improved
cardiac function without the effect on ventricular remodelling.
The greatest similarity of physiological mechanisms lies
with adrenergic b-blockers, which reduce the heart rate and
reduce the chronic hyper-adrenergic state that is typical
of heart failure(45), thereby reducing energy requirements.
However, although fish oils can reduce intrinsic heart rate
and prevent sudden death in rats associated with chronic iso-
prenaline treatment(39), they have no b-adrenoceptor antagon-
ist action(46), and unlike b-blockers, heart rate reduction is
achieved independently of sympathetic nervous activity(12,16).
In common with n-3 PUFA, b-blockers facilitate chronic
intrinsic improvements in cellular function in hypertrophied
cardiomyocytes by improvements in cellular energetics(19) or
intracellular Ca2þ handling(43).
Thus, dietary fish oil improved cardiac function in hyper-
trophied hearts in a manner that contrasts to the currently
available suite of treatments used to stimulate the heart
or counteract dysfunction. It appears to have an intrinsic
effect on myocardial cellular function independent of cardiac
unloading or slowed heart rate, to improve contractility
without adverse energetic consequences and independently
of modulating the hypertrophy.
Therapeutic implications
Epidemiological evidence showing a reduced risk of incident
heart failure in people who regularly eat fish(7,47) is now sup-
ported by a large secondary prevention clinical trial in which
n-3 PUFA supplementation reduced mortality and hospitalis-
ation in heart failure in the context of usual care(48), which
included simultaneous treatment with many of the therapeutic
agents discussed above. The findings of the present study
begin to explain not only the original GISSI-HF outcomes
but also a recent subset evaluation of the GISSI-HF trial(48)
which noted that the reduced number of hospital admissions
due to cardiovascular reasons in heart failure was paralleled
by improved cardiac function without the evidence of reverse
remodelling(49).
Animal and human studies have suggested that a ceiling
exists for the cardiac effects of n-3 PUFA(50,51), which in
animals reflects maximum incorporation of DHA into myo-
cardial membranes(23,52). Thus, the effects reported here for
5 % dietary fish oil are probably achievable at lower
intakes(24,50,53), in line with even very low increases in fish
oil intake, commensurate with human dietary intake, to
increase myocardial membrane n-3 PUFA incorporation(23).
An absence of n-3 PUFA from the diet amplifies the cardiac
depressant effects of ischaemic or hypertrophic stress. This
can be overcome by incorporating fish oil in the diet to
improve myocardial energetics, which is identified as a new
candidate approach to the treatment of heart failure(19).
When combined with the amelioration of risk for sudden
heart attack death and antihypertrophic actions, amelioration
of heart failure adds a new dimension to the nutritional pre-
conditioning properties of fish oil fatty acids(16).
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